Prepared by R.R. Donnelley Financial -- Form 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 30, 2002
NEOTHERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Charter)
| Delaware |
|
000-28782 |
|
93-0979187 |
| (State or Other Jurisdiction of Incorporation) |
|
(Commission File
Number) |
|
(I.R.S. Employer Identification
No.) |
157 Technology Drive
Irvine, California 92618
(Address of Principal Executive Offices)
(949) 788-6700
(Registrant’s telephone number, including area code)
ITEM 5. OTHER EVENTS
On October 1, 2002, NeoTherapeutics, Inc. (the “Company”) issued a press release announcing that it has signed an agreement with GPC Biotech AG to co-develop
NeoTherapeutics’ lead anti-cancer drug satraplatin. The text of the press release is set forth in Exhibit 99.1 attached to this report and incorporated herein by this reference.
ITEM 7. EXHIBITS
| Exhibits:
|
|
|
| 99.1 |
|
Press release dated October 1, 2002. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 1, 2002
| NEOTHERAPEUTICS, INC. |
| |
| By: |
|
/s/ Rajesh Shrotriya
|
| |
|
Name: Rajesh C. Shrotriya, M.D. Title: Chairman of the Board, Chief Executive Officer and President |
3
EXHIBIT INDEX
| Exhibits:
|
|
|
| 99.1 |
|
Press release dated October 1, 2002. |
4